Liqomics, MRD, minimal residual disease, cancer treatment assessment, liquid biopsy, lymphoma, ctDNA, cfDNA, cell-free DNA, circulating tumor DNA, Hodgkin lymphoma, liquid biopsy company, mrd monitoring, cancer testing, MRD test

Call Us

(+49) 221 69 056 597

GET A QUOTE
Linkedin Youtube

Publications

Here are some publications from our early development showing applications in various lymphomas.

Heger et al

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood (2024) 143 (6): 522–534. (LINK: https://doi.org/10.1182/blood.2023022020)

Sobesky et al

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection. Med (2021) 2 (10), 1171-1194. (LINK: https://doi.org/10.1016/j.medj.2021.09.002)

Heger et al

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. Journal of Clinical Oncology (2024) (LINK: https://doi.org/10.1200/JCO.23.01867)

Mattlener et al

Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma. Blood (2024) 144 (Supplement 1): 4355. (LINK: https://doi.org/10.1182/blood-2024-205034)

Schleifenbaum et al

Serial monitoring of circulating tumor DNA with an ultrasensitive assay facilitates outcome prediction in RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA treated with modern agents. 05/14/24 EHA library. (LINK: https://library.ehaweb.org/eha/2024/eha2024-congress/419348/julia.k.schleifenbaum.serial.monitoring.of.circulating.tumor.dna.with.an.html)

Conference Talks

We presented validation data for LymphoVista and LymphoVista HL at the International Symposium on Hodgkin Lymphoma (ISHL) 2024 in Cologne, Germany and at the American Society of Hematology (ASH) meeting 2024 in San Diego, USA

Webinars

April 28, 2025. Recap: "Liquid Biopsy and MRD – An Introduction"

Thank you to everyone who joined us on Monday, April 28, for our insightful webinar on Liquid Biopsy and Minimal Residual Disease (MRD)! We explored the fundamentals, applications, and latest advancements in this transformative field of diagnostics.

Stay tuned – we’ll be announcing the date for our next webinar soon! Want to be the first to know? Subscribe here to receive updates and exclusive content.

Interested in diving deeper? Contact us to discuss how Liqomics’ solutions can support your research or clinical trials.

Videos

Playlist

11 Videos
Liqomics, MRD, minimal residual disease, cancer treatment assessment, liquid biopsy, lymphoma, ctDNA, cfDNA, cell-free DNA, circulating tumor DNA, Hodgkin lymphoma, liquid biopsy company, mrd monitoring, cancer testing, MRD test

At LIQOMICS we strive to improve cancer treatment. Requiring only a blood sample, we use circulating tumor DNA to understand the genetics of an individual cancer and monitor treatment with razor-sharp sensitivity.

Other Pages

Contact Details

  • (+49) 221 69 056 597
  • LIQOMICS GmbH Hermülheimer Str. 68 50969 Köln
    Germany

Follow us

Linkedin Youtube

Email us

contact[at]liqomics.com

Copyright © 2025 All rights reserved.
REQUEST QUOTE